Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00765024 | Ivermectin Versus Albendazole for Chronic Strongyloidiasis | PHASE3 | COMPLETED | 90 | — | — | Jul 1, 2008 | Apr 1, 2010 | Sep 7, 2017 | 1 | Thailand |
| Arm | Type | Description |
|---|---|---|
| Albendazole | ACTIVE_COMPARATOR | Albendazole for 7 days |
| ivermectin | EXPERIMENTAL | ivermectin 200 mcg/kg single dose |
| ivermectin 2 doses | EXPERIMENTAL | ivermectin 200 mcg/kg two doses in 2 weeks |
| Name | Type | Description |
|---|---|---|
| Ivermectin | DRUG | single dose of 200 mcg/kg |
| Albendazole | DRUG | Albendazole 7 days |
Inclusion Criteria: * Patients with positive strongyloides larva in the stool Exclusion Criteria: * Pregnancy * Lactating women * Known allergy to any study drug